Table 2

Vaccine Preventability of Meningococcal Clone, Greater Aachen Region, Germany

Johannes Elias

, Leo M. Schouls, Ingrid van de Pol, Wendy C. Keijzers, Diana R. Martin, Anne Glennie, Philipp Oster, Matthias Frosch, Ulrich Vogel¹, and Arie van der Ende¹

Author affiliations: University of Wuerzburg, Wuerzburg, Germany (J. Elias, M. Frosch, U. Vogel); National Institute for Public Health and Environment (RIVN), Bilthoven, the Netherlands (L.M. Schouls, I. van de Pol); Academic Medical Center, Amsterdam, the Netherlands (W.C. Keijzers, A. van der Ende); Institute of Environmental Science and Research, Porirua, New Zealand (D.R. Martin, A. Glennie); Novartis Vaccines, Siena, Italy (P. Oster)

Main Article

Serum bactericidal antibody titers before and after vaccination with MeNZB against German strain DE9686, Greater Aachen Region, Germany, 2001–2006*

Age group	No. vaccinees	Before	After	4-fold rise	>8 post
8–12 y	1	12	1,727	←	←
	2	3	104	←	←
	3	189	406	–	←
	4	50	296	←	←
	5	229	729	–	←
	6	23	175	←	←
	7	9	84	←	←
	8	2	213	←	←
	9	2	77	←	←
	10	2	55	←	←
18–24 mo	11	2	214	←	←
	12	4	45	←	←
	13	2	109	←	←
	14	7	92	←	←
	15	2	306	←	←
	16	6	431	←	←
	17	2	216	←	←
	18	3	44	←	←
	19	3	218	←	←
	20	2	171	←	←

*– represents cases where conditions 4-fold rise and >8 post are false. Arrows represent cases where conditions 4-fold rise and >8 post are true.

Main Article

¹These authors contributed equally to this article.

Page created: December 14, 2010

Page updated: December 14, 2010

Page reviewed: December 14, 2010

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.